This study analyzed 550 hemodialysis patients, 469 unvaccinated and 81 vaccinated against COVID-19, to assess the impact on infection rates, mortality, and clinical/laboratory parameters. Gender distribution was similar (p = 0.209), but the vaccinated group’s median age was significantly lower (p = 0.005). Hospitalization rates showed no significant difference (p = 0.987), while mortality was lower in the vaccinated group (p = 0.041). Only uric acid levels were significantly higher in the vaccinated group (p = 0.009); other parameters, including creatinine and B-type natriuretic peptide, showed no significant differences. Age was an independent predictor of mortality (HR = 1.07, p < 0.001). Peak mortality occurred in December 2022 and January 2023, predominantly among unvaccinated patients. Although vaccination lowered mortality, it did not significantly affect long-term survival rates (p = 0.308). Logistic regression identified age and dialysis duration as significant mortality factors. Monthly death counts indicated higher mortality among unvaccinated patients during peak pandemic months, suggesting that vaccination provides some protection, though no significant long-term survival benefit was found.

Maintenance hemodialysis patients are at increased risk of cardiovascular complications and mortality following COVID-19 infection due to compromised immune function. This study aims to evaluate the impact of the COVID-19 vaccine (CoronaVac) on cardiac function and survival in this population. Background/Objectives: We aimed to examine whether CoronaVac vaccination affects heart function and survival rates in maintenance hemodialysis patients. Specifically, we assessed changes in heart ultrasound (echocardiographic) measurements, B-type natriuretic peptide (BNP) levels, and survival outcomes by comparing vaccinated and unvaccinated patients. Methods: A retrospective analysis was conducted on 531 maintenance hemodialysis patients, including 79 who received CoronaVac and 452 who did not. We compared the pre- and post-infection changes in heart function (echocardiographic parameters) and BNP levels between the two groups and assessed their association with the survival rates. Results: The vaccinated patients were younger (60.54 ± 13.51 vs. 65.21 ± 13.76 years, p = 0.006) and had shorter dialysis durations (56.04 ± 51.88 vs. 73.73 ± 64.79 months, p = 0.022). The mortality rate was also significantly lower in the vaccinated group (6.33% vs. 14.38%, p = 0.049). After infection, the unvaccinated patients showed significant declines in heart function and increased B-type natriuretic peptide levels, while the vaccinated patients demonstrated no significant deterioration. Older age, coronary artery disease, inflammation levels, and heart abnormalities were identified as the key risk factors for mortality. Conclusions: CoronaVac was linked to lower mortality and better heart function in maintenance hemodialysis patients. The vaccine may help to reduce infection severity, lower strain on the heart, and improve the overall prognosis.